Market Overview

PiperJaffray Reiterates Overweight, $31 PT On Masimo


In a note out today, PiperJaffray reiterated an overweight rating and $31 price target on medical device maker Masimo (Nasdaq: MASI). That price target implies more than 50% upside from where the shares currently reside. Masimo recently participated in PiperJaffray's annual healthcare conference.

“Masimo's CFO, Mark de Raad, provided a favorable business update, describing reaccelerating business trends in November (new contracts and higher volumes), despite continued business head-winds. Management described expectations for longer-term benefits from the recent sensor upgrade, new resposable sensor launch (mid-2012) and continued progress with OEM adoption of Rainbow,” PiperJaffray said in a note.

Posted-In: Analyst Color News Price Target Reiteration Intraday Update Markets Analyst Ratings Trading Ideas


Related Articles (MASI)

View Comments and Join the Discussion!

Latest Ratings

WEEDCantor FitzgeraldMaintains18.9
TGTXCantor FitzgeraldMaintains19.0
SPLKCleveland ResearchDowngrades
IQVWolfe ResearchUpgrades
PRAHWolfe ResearchUpgrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Sterne Agee Expecting Upside for Tiffany & Co. Through Holiday Season

Five Stocks That Could Be Impacted by AMR's Bankruptcy